Kornimate/medical-research-clean huggingface dataset:
the effectiveness of neurodynamic techniques in patients with nerve-related leg pain

Conditions: Nerve Pain; Peripheral Nerve Injuries; Peripheral Nervous System Diseases; Sciatica; Low Back Pain; Low Back Ache; Signs and Symptoms

Summary: this study aims to verify if patients with nerve-related leg pain benefits from neurodynamic treatment over two weeks.

nerve-related leg pain (nrlp) although less prevalent than low back pain itself, is associated with higher economic and social burden, and has been considered a predictor of chronicity and disability among subjects with low back pain. numerous approaches are proposed for its management; however, evidence regarding the best therapeutic approach is lacking. neurodynamic techniques are proposed to be effective to manage nrlp. thus, this study aims to verify, through a randomized controlled trial, the effectiveness of a two-week program of neurodynamic techniques on pain and disability in individuals with nrlp.

Eligibility criteria:
inclusion criteria: * unilateral leg pain (intensity ≥ 3) * pain distal to the buttocks * reproduction of symptoms and change in symptoms with structural differentiation (cervical return to neutral position or ankle dorsiflexion) with slump test; exclusion criteria: * cauda equina syndrome; * bilateral leg pain; * crossed lasègue sign; * previous surgery in the lumbar spine; * inflammatory arthropathies; * malignancy * being in litigation or in work-compensation due to back and/or leg pain * being receiving physiotherapy treatment at the time of baseline assessment

Keywords: sciatica nerve pain low back pain
trial of continuous once daily oral treatment using bibw 2992 (afatinib) plus sirolimus (rapamune®) in patients with non-small cell lung cancer harbouring an egfr mutation and/or disease progression following prior erlotinib or gefitinib

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the primary objective of this trial is to identify the maximum tolerated dose of bibw 2992 therapy when given continuously in combination with sirolimus. the mtd will be based on the dose limiting toxicity information collected during the first two cycles. overall safety, pharmacokinetics and anti-tumour efficacy will be evaluated as secondary objectives.


Eligibility criteria:
inclusion criteria: 1. pathologically or cytologically confirmed diagnosis of stage iiib or stage iv nsclc 2. patients who have failed conventional treatment (at least 1 prior treatment line), or for whom no therapy of proven efficacy exists 3. patients whose tumors: * are egfr mutation-positive or * are egfr mutation-negative or unknown provided they had disease progression after achieving either response or stable disease for at least 6 months from a previous treatment with erlotinib (tarceva®) or gefitinib (iressa®) 4. patients aged 18 years or older 5. life expectancy of at least three (3) months 6. eastern cooperative oncology group (ecog, r01-0787) performance score 0-2 7. written informed consent that is consistent with ich-gcp guidelines exclusion criteria: 1. prior major surgery, chemotherapy or radiation therapy within 4 weeks before start of therapy. 2. prior treatment with an mtor inhibitor within the past 4 weeks before start of therapy or concomitantly with this study 3. use of erlotinib (tarceva®) or gefitinib (iressa®) within 14 days of run-in treatment with sirolimus 4. active cns metastases (defined as stable for \<4 weeks and/or symptomatic and/or requiring treatment with anticonvulsants or steroids) 5. severe alteration in serum fasting cholesterol (equal or more than 350 mg/dl) or triglycerides (equal or more than 400 mg/dl). patients may be allowed to enrol on the trial after initiation of lipid lowering agents. 6. requirement for treatment with any of the prohibited concomitant medications: * concomitant cyp3a4 inhibitors within the past 7 days before start of therapy or concomitantly with this study. * concomitant cyp3a4 inducers within the past 14 days before start of therapy or concomitantly with this study. 7. any contraindications for therapy with sirolimus. 8. known hypersensitivity to bibw 2992, sirolimus or other rapamycin analogues (everolimus, temsirolimus, deforolimus, etc.) or the excipients of any of the trial drugs. 9. use of any investigational drug within 4 weeks before start of therapy.
shared decision making in older adults with distal radius fractures

Conditions: Radius Fracture

Summary: this is a study to investigate the use of a decision aid for shared decision making in older adults with distal radius fractures. the goal is to improve patient decisions making, and improve patient knowledge through the use of a validated decision aid.

shared decision making has become a increasingly important with the goal of helping patients make decisions that more align with patients values and goals. decision aids are validated instruments that provide unbiased information and guide patients through questions that allow patients to clarify patients goals. older adults with distal radius fractures have increasing evidence of ability to tolerate residual deformity with little to no functional deficits, which has called into question the indications for surgery. in situations where the operative indications are not clear, it is important to engage the patient in the risk and benefits of the decision. this trial is a prospective trial with two groups, one standard of care, and one with the decision aid.

Eligibility criteria:
inclusion criteria: * distal radius fracture within the past 2 weeks * initial appointment seeing attending * age 65+ exclusion criteria: * non english speaker * dementia or other mental limitation preventing ability to complete survey * other traumatic injuries in extremity that would affect surgical decision

Keywords: decision aid shared decision making older adult patients distal radius fracture
the role of narrow-band imaging endoscopy in diagnosing gastric intestinal metaplasia

Conditions: Dyspepsia

Summary: the purpose of this study is to determine if endoscope with nbi(narrow banding imaging)can detect intestinal metaplasia( consider pre malignant condition) and use a targeting biopsy in case of suspected intestinal metaplasia

to detect intestinal metaplasia which consider pre malignant condition and use a targeting biopsy in case of suspected intestinal metaplasia which allowed us to better follow-up those patients.

Eligibility criteria:
inclusion criteria: * dyspepsia exclusion criteria: * pregnancy, * upper gastrointestinal bleeding, * previous gastric operation, * known gastric malignancy' * non cooperative patients

Keywords: nbi gastroscopy biopsy intestinal metaplasia
the igfbp-3 stimulation test: a new tool for the diagnosis of growth hormone deficiency in children.

Conditions: Short Stature; Growth Hormone Deficiency

Summary: this project is designed to answer the question: is there an acute igfbp-3 response in normal children? our specific hypothesis states that under the influence of growth hormone secretagogues, intact igfbp-3 molecule will undergo proteolysis and liberate igfbp-3 fragments, along with other components of the ternary complex. this proteolysis will result in measurable rise in igfbp-3, which will indicate the subject's growth hormone status. short children with growth hormone deficiency will not show an igfbp-3 response.

the diagnosis of growth hormone deficiency is problematic, given the shortcoming of the standard growth hormone stimulation test. this study is designed to investigate a new tool for the diagnosis of growth hormone deficiency. ten short, prepubertal children, who fulfill the inclusion criteria, will undergo a two-secretagogue standard growth hormone stimulation test, and an insulin like growth factor binding protein-3 (igfbp-3) stimulation test simultaneously. during this test, components of the ternary complex moieties, viz, insulin-like growth factor-i (igf-i), igfbp-3 and acid labile subunit (als) will also be measured along with growth hormone. the aim of this study is to detect an acute rise in igfbp-3 of \>15% from baseline. the importance of this study is that it inculcates the specificity and improved sensitivity of stimulated igfbp-3 in the diagnosis of growth hormone deficiency.

Eligibility criteria:
inclusion criteria: * bone age \< 10 years female, \< 12 years male * pubertal status: girls: tanner i for breast development. boys: testicular volume of ≤ 3 cc, as measured by the standardized orchidometer (prader type). the onset of pubic hair development up to and including tanner iii is allowed in the study. * adequate nutrition: body mass index ≥ 25th percentile for gender. exclusion criteria: * syndromic short stature * chronic illnesses. * other disorders, including osteo- or chondrodystrophies, and endocrine causes of short stature such as cushing syndrome, and untreated hypothyroidism.

Keywords: growth hormone deficiency
outcome evaluation for burn scar therapy-laser and surgery in patients in formosa fun coast explosion

Conditions: Patients With Major Burn Injury in Formosa FunCost Explosion

Summary: protocol title： outcome evaluation for burn scar therapy-laser and surgery in patients in formosa fun coast explosion objectives： the goal of this study is to evaluate the effectiveness of both lasers and operations on patients with major burn scar(\>20% tbsa).

background： there is no gold standard treatment for burn scar treatment, especially for those with major burn scar. in the formosa fun-coast dust explosion in 2015, lots of patients with major burn scar suffer from severe pathologic burn scar syndromes. the gold of the study is to evaluate the efficacy of both lasers and operations on major burn scars treatment in the past two years. study design： to take the assessment of scar into account, the investigators use both objectives and subjective methods to evaluate the scar condition. in addition to the scale of scar, the investigators also use both sonography and hrv system to evaluate the expressions of scar. all evaluated tools used are the same as those used in 20160201r and 20160202r. the investigators also used previous records to check the patient's scar condition before these treatments. hypothesis： after treatment, scar conditions should get better than before. however, the investigators need more scientific statistics to evaluate the improve rate. key words： burn scar, burn scar syndromes. scar laser treatment

Eligibility criteria:
inclusion criteria: 1. \>20% major burn scar, for 3 years 2. patients in formosa funcost explosion 3. offering medical records, including laser and treatments 4. available for questionnaire evaluation and others' evaluation 5. those are willing to receive both sonography on scars and hrv evaluation exclusion criteria: 1. those aren't willing to offer medical records 2. those aren't willing to fill questionnaire 3. those aren't willing to receive sonography on scars

Keywords: burn scar laser ultrapulse
effect of transauricular vagus nerve stimulation on postoperative pain management in video assisted thoracic surgery

Conditions: Postoperative Pain, Acute; VATS

Summary: transcutaneous auricular vagus nerve stimulation (tavns) is a novel pain management technique that has gained popularity in recent years due to its non-invasive nature and ease of operation. current literature has substantiated its efficacy in managing pain syndromes and chronic pain. however, there is a paucity of evidence regarding its effectiveness in treating acute postoperative pain. this project aims to explore the efficacy of tavns in postoperative pain management, with a focus on video-assisted thoracic surgery(vats). the investigators have designed a double-blind, single-center, randomized controlled clinical trial, planning to enroll 116 patients scheduled to undergo vats(including segmentectomy or lobectomy) under general anesthesia at peking union medical college hospital. participants will be divided into an intervention group (receiving tavns) and a sham intervention group (receiving sham-tavns), and will undergo a 2-hour intervention on the first postoperative day. the primary outcome is the pain relief rate, defined as a reduction of 15mm or 30% in the vas (1-100mm) score immediately before and after the intervention on the first postoperative day. secondary outcomes include: the proportion of patients with inadequate analgesia within three days after intervention; the difference in vas scores immediately before and after the intervention on the first postoperative day; the incidence of opioid-related and tavns-related side effects from the first to the third postoperative day after intervention; the number of effective and ineffective pca presses (if used) from the first to the third postoperative day after intervention; the specifics and frequency of additional analgesic measures taken by patients from the first to the third postoperative day after intervention; the difference in rcsq scores on the night of surgery and the night after intervention; and the probability of patients experiencing surgery-related pain three months after surgery. follow-up period for this study will be three months after surgery.


Eligibility criteria:
inclusion criteria: 1. age 18 years or older; 2. asa classification i-iii; 3. no prior tavns treatment; 4. scheduled to undergo vats (including segmentectomy and lobectomy); 5. vas ≥ 30 mm at any time on the day of surgery; 6. patients and their families can understand the study design and are willing to cooperate and participate in the study. exclusion criteria: 1. psychiatric disorders or other conditions that prevent cooperation; 2. long-term use of steroids or opioids; 3. scheduled for bilateral vats surgery; 4. history of thoracic surgery; 5. history of chronic pain, autoimmune diseases, or persistent infections. withdrawl criteria: 1. patient request; 2. surgery cancellation or change in surgical method resulting in failure to meet inclusion criteria; 3. severe perioperative complications and adverse events; 4. severe intervention-related adverse events.

Keywords: tavns postopearvie pain vats
mda d-dimer / recurrent dvt study

Conditions: Deep Vein Thrombosis

Summary: to determine whether treatment and further investigation can be safely withheld in patients who present with suspected recurrent deep vein thrombosis (dvt) and have either a (i) negative d-dimer or (ii) a positive d-dimer with normal serial compression ultrasound.


Eligibility criteria:
inclusion criteria: * age 18 or older * currently suspected for recurrent dvt * has a prior history of objectively documented dvt or pe exclusion criteria: * comorbid condition limiting survival to less than 3 months * history of hypersensitivity to contrast medium * renal dysfunction with a creatinine of \> 150 mcmol/l * treatment with full-dose therapeutic unfractionated or low molecular weight heparin that was initiated 24 hours or more prior to eligibility assessment * pregnancy or lactation * symptomatic for pulmonary embolism * absence of symptoms within five days prior to presentation * participation in another trial precluding the use of the diagnostic algorithm in this study * geographically inaccessible for follow-up * compression ultrasound, venogram, ipg, or d-dimer performed prior to assessment

Keywords: deep vein thrombosis dvt
accuracy of prediction equations to calculate maximum strength

Conditions: Healthy Aging

Summary: resistance exercise training (rt) is a key component of health related exercise programs. however, an accurate specification of rt load prescription is essential for effective and safe achievement of training aims. proper specification of exercise intensity might be the most critical issue when designing rt protocols for adults. one repetition maximum tests (1rm) have been considered the "gold standard" of dynamic maximum strength evaluation. although the argument of increased risk of injuries and adverse effects with 1rm testing in older people has been rejected by several studies , limited motivation to lift maximum loads, requirement for high test effort, time constraints, and interruption of the continuity of the training process aggravate the frequent application of 1rm tests particularly in non-athletic rt. 1rm prediction equations that use the load and number of repetitions completed to fatigue (rtf) to predict repetition maximum might be a reliable and feasible option to 1rm testing. thus, the primary aims of this study were to evaluate the predictive accuracy of current rtf equations and to develop an equation that more accurately predicts 1rm from rtf tests.


Eligibility criteria:
inclusion criteria: * 18 to 35 years old * 60 to 85 years old exclusion criteria: * contraindication for one repetition maximum tests * musculoskeletal injuries that may prevent a reliable and safe assessment of the 1rm and rtf tests

Keywords: maximum strength one repetition maximum repetitions to fatigue prediction equation resistance exercise
toothpaste with sodium carbonate in patients with gingivitis

Conditions: Gingivitis; Periodontal Diseases

Summary: sodium carbonate has several properties that may be beneficial in the management of bacterial biofilm in gingivitis patients. the aim of this rct study is to clinically evaluate the clinical properties of two toothpaste containing sodium carbonate 67% and fluoride toothpaste that contains no bicarbonate on patients with gengivitis.

sodium carbonate has several properties that may be beneficial in the management of bacterial biofilm in both gingivitis and periodontitis patients. the aim of this rct study is to clinically evaluate the clinical properties of two toothpaste containing sodium carbonate at 67% or no sodium carbonate at 67% at 6-month follow-up in patients with gingivits. the study was designed as a double-blind randomized controlled trial (rct) with 2 parallel groups of individuals.

Eligibility criteria:
inclusion criteria: * clinically diagnosed with gingivitis according to the efp/aap 2017 criteria. exclusion criteria: * periodontal treatment, antibiotics, nsaids, immunosuppressants during the last 6 months. * pregnancy. * systemic diseases.
molecular assessment of drug resistance markers in asymptomatic malaria cases and malaria antibody kinetic

Conditions: Increased Drug Resistance; Asymptomatic Infection; Malaria

Summary: detection of the drug resistance molecular markers for falciparum and vivax in longitudinal follow-up samples collected in shwegyin township, bago region that is artemisinin resistance containment tier i.

this study is longitudinal and observational cohort study to detect the drug resistance molecular markers in asymptomatic malaria infected local residents in study site. only local residence who are not migrants, are recruited in the study and active and passive surveillance have been carried out within one year observation period. at the time of enrollment, blood film examination, rapid diagnosis test (rdt) testing have been done all together with the collection of the venous blood (about 1-2 ml) that would be used for molecular analysis later. all of the rdt or microscopy positive cases were treated according to the national malaria treatment policy in myanmar. a total of at least 1000 participants have been recruited in the study. active case detection has been done in every three months. the venous blood were used for molecular based detection of the asymptomatic malaria infection by using high-throughout pooling strategy. all of the positive samples, (falciparum and vivax), have been checked for drug resistance molecular analaysis compared with the previously collected symptomatic malaria infection cases in the same region.

Eligibility criteria:
inclusion criteria: * local resident in stud sites * who give informed consent * no known tentative plan to move/ migrant elsewhere within one year exclusion criteria: * migrant or mobile population * less than 6 year

Keywords: drug resistance malaria myanmar artemisinin resistance containment zone asymptomatic malaria serology
time efficiency comparison of two intravitreal injection techniques

Conditions: Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion With Macular Edema; Uveitic Macular Edema; Choroidal Neovascularization

Summary: prospective, single-center, randomized, clinical trial (rct) comparing the time efficiency and safety of a single-use intravitreal injection (ivi) guide versus a traditional technique using a dual blade speculum among patients undergoing ivi for various indications.

prospective, single-center, randomized, clinical trial (rct) comparing the efficiency and safety of a single-use iig with a traditional technique using a dual blade speculum among patients undergoing ivi for various indications. the investigators will include eyes of adult patients scheduled to undergo unilateral ivi for neovascular age-related macular degeneration (namd), polypoidal choroidal vasculopathy (pcv), diabetic macular edema (dme), retinal vein occlusion (rvo), choroidal neovascular membrane from pathologic myopia (pm) and uveitis. the investigators will exclude eyes with a history of extraocular or intraocular infection within 3 months of the scheduled ivi date, scleral thinning, history of previous glaucoma surgery, history of pars plana vitrectomy, hypersensitity to the ivi drug, propracaine or povidone iodine, and inability to understand the informed consent form. the eyes will be randomly assigned in 1:1 fashion into two injection arms: intravitreal injection guide (iig) and dual blade speculum (dbs). at the time of injection, a random number generator will be used to generate an odd or even number for each eye. odd eyes will be assigned to iig and even eyes will be assigned to dbs. for same day bilateral injection, once the first eye is randomized to one technique, the second eye will be automatically assigned to the other technique. the study will be conducted in compliance with the declaration of helsinki. all patients will provide informed consent prior to start of study procedures.

Eligibility criteria:
inclusion criteria: \* eyes of adult patients requiring intravitreally injected medications for non-infectious indications exclusion criteria: * history of extraocular or intraocular infection within 3 months of the scheduled ivi date * scleral thinning * history of previous glaucoma surgery * history of pars plana vitrectomy * hypersensitivity to the ivi drug, proparacaine or povidone iodine * inability to understand the informed consent form

Keywords: intravitreal injection intravitreal injecton guide macular edema time efficiency anti-vegf